In summary, we have demonstrated in this paper that HCC patients with high PAK1 expression had shorter survival and that PAK1 was crucial in the tumour growth and metastasis of HCC, contributing to resistance to Sorafenib. The gene discussed is PAK1; the disease is hepatocellular carcinoma.